| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA3718776
Max Phase: Preclinical
Molecular Formula: C20H24N6O2S
Molecular Weight: 412.52
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: O=C(N[C@H]1CCCNC1)c1ccnc2nc(-c3cc(N4CCC(O)C4)cs3)[nH]c12
Standard InChI: InChI=1S/C20H24N6O2S/c27-14-4-7-26(10-14)13-8-16(29-11-13)18-24-17-15(3-6-22-19(17)25-18)20(28)23-12-2-1-5-21-9-12/h3,6,8,11-12,14,21,27H,1-2,4-5,7,9-10H2,(H,23,28)(H,22,24,25)/t12-,14?/m0/s1
Standard InChI Key: BPDWULHLPNCDQC-NBFOIZRFSA-N
Associated Targets(Human)
PDZ-binding kinase 995 Activities
T47D 39041 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
HT1197 222 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 412.52 | Molecular Weight (Monoisotopic): 412.1681 | AlogP: 1.74 | #Rotatable Bonds: 4 |
| Polar Surface Area: 106.17 | Molecular Species: BASE | HBA: 7 | HBD: 4 |
| #RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 7.64 | CX Basic pKa: 9.53 | CX LogP: -0.72 | CX LogD: -1.55 |
| Aromatic Rings: 3 | Heavy Atoms: 29 | QED Weighted: 0.52 | Np Likeness Score: -0.98 |
References
| 1. (2011) Imidazopyridine derivatives and pbk inhibitors containing the same, |
Source
Source(1):